Healthcare / BiotechnologyNasdaqCM
$0.80
-0.03 (-4.11%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-3.0M · quality 49.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
27/100
D
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$9M
P/E
0.3x
↓EV/EBITDA
N/A
•ROE
59.1%
↑Gross Margin
N/A
•Debt/Equity
N/A
•TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2011–2025 · 14 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
—
FCF / Net income
-0.10x
Latest source
Provider fallback
Margin decomposition
Último año: revenue — · net income $30.7M · FCF $-3.0M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||||||||
| Revenue | — | — | — | — | — | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $12160.00 | $66558.00 | $75997.00 |
| Net Income | $30.7M | $30.7M | $333763.00 | $-4.3M | $-4.2M | $-3.6M | $-3.8M | $-4.1M | $-6.8M | $-4.4M | $-6.1M | $-9.9M | $-27.3M | $-1.6M | $-1.9M | $-1.4M |
| EBITDA | $-4.4M | $-4.4M | $-6.5M | $-6.5M | $-4.2M | — | — | — | — | — | — | — | — | $-1.7M | $-1.9M | — |
| EPS | 3.19 | 3.19 | -1.80 | -0.22 | -0.27 | -2.45 | — | — | — | — | — | — | -77.50 | 0.00 | -15.50 | 0.00 |
| Gross Margin | — | — | — | — | — | — | — | — | — | — | — | — | — | 20.9% | 70.9% | 123.5% |
| Operating Margin | — | — | — | — | — | — | — | — | — | — | — | — | — | -13851.7% | -2928.5% | — |
| Net Margin | — | — | — | — | — | — | — | — | — | — | — | — | — | -13142.3% | -2853.6% | -1839.2% |
| Balance Sheet | ||||||||||||||||
| Current Ratio | 12.33 | 12.33 | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Cash Flow | ||||||||||||||||
| Free Cash Flow | $-3.0M | $-3.0M | $-2.2M | $-3.8M | $-4.1M | — | — | — | — | — | — | — | — | — | — | — |
| Returns | ||||||||||||||||
| ROE | 59.1% | 59.1% | 0.8% | -5.9% | -4.7% | -53.2% | -75.2% | -80.7% | -118.4% | -54.9% | -93.0% | -127.7% | -304.8% | 106.4% | 83.3% | 51.2% |
| Valuation | ||||||||||||||||
| P/E | 0.25 | 0.25 | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| P/B | 0.11 | 0.11 | 0.52 | 0.75 | 0.37 | — | — | — | — | — | — | — | — | — | — | — |
| Growth & Yield | ||||||||||||||||
| Revenue Growth | — | — | — | — | — | — | — | — | — | — | — | — | -100.0% | -81.7% | -12.4% | — |
| EPS Growth | 277.2% | 277.2% | -718.2% | 18.5% | — | — | — | — | — | — | — | — | — | 100.0% | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
-71.9%
EPS terminal req.
$0.07
Spread vs growth
349.1%
5Y implied EPS CAGR
-51.5%
EPS terminal req.
$0.09
Spread vs growth
328.7%
10Y implied EPS CAGR
-26.9%
EPS terminal req.
$0.14
Spread vs growth
304.2%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-22.0%
Start / end P/E
n/dx → n/dx
EPS bridge
-1.80 → 3.19
Residual
-22.0%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.